Author/Creator: Gordon, K. B. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Gordon, K. B.

1. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. (2nd January 2022)

Authors:: Gordon, K. B.; Reich, K.; Crowley, J. J.; Korman, N. J.; Murphy, F. T.; Poulin, Y.; Spelman, L.; Yamauchi, P. S.; Mendelsohn, A. M.; Parno, J.; Rozzo, S. J.; Ellis, C. N.
Journal:: Journal of dermatological treatment
Issue:: Volume 33:Number 1(2022)
Page Start:: 219
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. (1st December 2021)

Authors:: Reich, K.; Gordon, K. B.; Strober, B. E.; Armstrong, A. W.; Miller, M.; Shen, Y. K.; You, Y.; Han, C.; Yang, Y. W.; Foley, P.; Griffiths, C. E. M.
Journal:: British journal of dermatology
Issue:: Volume 185:Number 6(2021)
Page Start:: 1146
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. (8th September 2021)

Authors:: Reich, K.; Gordon, K. B.; Strober, B. E.; Armstrong, A. W.; Miller, M.; Shen, Y. K.; You, Y.; Han, C.; Yang, Y. W.; Foley, P.; Griffiths, C. E. M.
Journal:: British journal of dermatology
Issue:: Volume 185:Number 6(2021)
Page Start:: 1146
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. (16th November 2012)

Authors:: Langley, R.G.; Papp, K.; Gottlieb, A.B.; Krueger, G.G.; Gordon, K. B.; Williams, D.; Valdes, J.; Setze, C.; Strober, B.
Journal:: Journal of the European Academy of Dermatology and Venereology
Issue:: Volume 27:Number 10(2013:Oct.)
Page Start:: 1252
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗